Login to Your Account

NewCo News

X-Body Platform Yields First Lead Compound for AMD

By Catherine Shaffer
BioWorld Today Contributing Writer

Monday, December 5, 2011
At the IBC Antibody Engineering Conference in San Diego, X-Body Biosciences reported that it has discovered and optimized its first lead anti-angiogenesis compound, XB2202, from its DNA display and sequencing platform. The compound satisfied the requirements for a lead compound, including inhibition of receptor phosphorylation in renal carcinoma cells and inhibition of retinal pericyte migration, through its binding of platelet-derived growth factor receptor beta (PDGFRB).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription